Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Cher S Chuah"'
Publikováno v:
Gastro Hep Advances, Vol 2, Iss 6, Pp 788-798 (2023)
Background and Aims: Inflammatory bowel disease (IBD) is associated with increased circulating damage-associated molecular patterns, in particular, the highly pro-inflammatory mitochondrial DNA (mtDNA). Here, we study the importance of blood neutroph
Externí odkaz:
https://doaj.org/article/54c3abbc21154a52a47b0378933a9b8c
Autor:
Mathew Lyons, Ian D. Arnott, Nikolas Plevris, Philip Jenkinson, Cher S Chuah, Charlie W. Lees, Rebecca J Pattenden, Lynne M Merchant, Gareth R. Jones
Publikováno v:
Frontline Gastroenterol
ObjectiveTo establish the relationship between trough vedolizumab levels and outcomes during maintenance therapy.DesignCross-sectional service evaluation was performed on patients with inflammatory bowel disease (IBD) receiving maintenance vedolizuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3529ba5eea24a378602b5a527236d5bb
https://doi.org/10.1136/flgastro-2019-101197
https://doi.org/10.1136/flgastro-2019-101197
Autor:
Nikolas Plevris, Eleanor F Watson, Cher S Chuah, Rebecca J Pattenden, Philip Jenkinson, Lynne M Merchant, Charlie W. Lees, Gwo-Tzer Ho, Shahida Din, Ian D. Arnott, Gareth R. Jones, Mathew Lyons, Alan G. Shand, Colin L. Noble
Publikováno v:
Digestive diseases and sciences. 64(6)
Switching from Remicade to CT-P13 allows for significant cost savings and has been shown to be non-inferior to continued therapy with Remicade for the treatment of Crohn’s disease. The aim of this work was to prospectively evaluate clinical outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e5d06f5a5d23be0ba295004cceb54d
https://pubmed.ncbi.nlm.nih.gov/30725297
https://pubmed.ncbi.nlm.nih.gov/30725297
Autor:
Cher S Chuah, Ian D. Arnott, Gwo-Tzer Ho, Shahida Din, Charlie W. Lees, Mathew Lyons, Lynne M Merchant, Eleanor F Watson, Colin L. Noble, Gareth R. Jones, Alan G. Shand, Nikolas Plevris, Rebecca J Pattenden, Philip Jenkinson
Publikováno v:
Inflammatory bowel diseases. 25(6)
Adalimumab is an established treatment for Crohn's disease. Limited data are available regarding the relationship between adalimumab drug levels and serum/fecal markers of gut inflammation. We therefore aimed to characterize the relationship between
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9896d8df4759f7cffa957006902094c
https://pubmed.ncbi.nlm.nih.gov/30335139
https://pubmed.ncbi.nlm.nih.gov/30335139